Two independent studies found that, in KRAS mutant lung cancer cells, FGFR can mediate adaptive resistance to the MEK inhibitor trametinib (Kitai et al., 2016, Manchado et al., 2016). The gene discussed is KRAS; the disease is lung cancer.